Stadler WM - Search Results

1

Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.

Sonpavde G, Pond GR, Fougeray R, Choueiri TK, Qu AQ, Vaughn DJ, Niegisch G, Albers P, James ND, Wong YN, Ko YJ, Sridhar SS, Galsky MD, Petrylak DP, Vaishampayan UN, Khan A, Vogelzang NJ, Beer TM, Stadler WM, O'Donnell PH, Sternberg CN, Rosenberg JE, Bellmunt J. Sonpavde G, et al. Among authors: stadler wm. Eur Urol. 2013 Apr;63(4):717-23. doi: 10.1016/j.eururo.2012.11.042. Epub 2012 Nov 26. Eur Urol. 2013. PMID: 23206856 Free PMC article.

2

Serum interleukin-6 levels in metastatic renal cell cancer: correlation with survival but not an independent prognostic indicator.

Stadler WM, Richards JM, Vogelzang NJ. Stadler WM, et al. J Natl Cancer Inst. 1992 Dec 2;84(23):1835-6. doi: 10.1093/jnci/84.23.1835. J Natl Cancer Inst. 1992. PMID: 1433373 No abstract available.

3

Low-dose interleukin-2 in the treatment of metastatic renal-cell carcinoma.

Stadler WM, Vogelzang NJ. Stadler WM, et al. Semin Oncol. 1995 Feb;22(1):67-73. Semin Oncol. 1995. PMID: 7855621 Review. No abstract available.

4

The cure of bladder cancer: the need for multidisciplinary efforts.

Vogelzang NJ, Stadler W, Rukstalis D. Vogelzang NJ, et al. J Urol. 1994 Mar;151(3):605-6. doi: 10.1016/s0022-5347(17)35028-0. J Urol. 1994. PMID: 8308968 No abstract available.

5

Human renal cancer carcinogenesis: a review of recent advances.

Stadler W, Vogelzang NJ. Stadler W, et al. Ann Oncol. 1993 Jun;4(6):451-62. doi: 10.1093/oxfordjournals.annonc.a058550. Ann Oncol. 1993. PMID: 8394735 Free article. Review. No abstract available.

6

High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experience.

Shulman KL, Stadler WM, Vogelzang NJ. Shulman KL, et al. Among authors: stadler wm. Urology. 1996 Feb;47(2):194-7. doi: 10.1016/S0090-4295(99)80414-2. Urology. 1996. PMID: 8607232

7

A phase II study of subcutaneous recombinant human interleukin-4 in metastatic renal cell carcinoma.

Stadler WM, Rybak ME, Vogelzang NJ. Stadler WM, et al. Cancer. 1995 Nov 1;76(9):1629-33. doi: 10.1002/1097-0142(19951101)76:9<1629::aid-cncr2820760920>3.0.co;2-q. Cancer. 1995. PMID: 8635068 Clinical Trial.

8

Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract.

Carpinito GA, Stadler WM, Briggman JV, Chodak GW, Church PA, Lamm DL, Lange PH, Messing EM, Pasciak RM, Reservitz GB, Ross RN, Rukstalis DB, Sarosdy MF, Soloway MS, Thiel RP, Vogelzang N, Hayden CL. Carpinito GA, et al. Among authors: stadler wm. J Urol. 1996 Oct;156(4):1280-5. J Urol. 1996. PMID: 8808854 Clinical Trial.

9

Metastatic bladder cancer: advances in treatment.

Stadler WM, Kuzel TM, Raghavan D, Levine E, Vogelzang NJ, Roth B, Dorr FA. Stadler WM, et al. Eur J Cancer. 1997 Jan;33 Suppl 1:S23-6. doi: 10.1016/s0959-8049(96)00337-1. Eur J Cancer. 1997. PMID: 9166096 Review.

10

Granulocyte-macrophage--colony stimulating factor in metastatic renal cell carcinoma: a phase II trial.

Rini BI, Stadler WM, Spielberger RT, Ratain MJ, Vogelzang NJ. Rini BI, et al. Among authors: stadler wm. Cancer. 1998 Apr 1;82(7):1352-8. doi: 10.1002/(sici)1097-0142(19980401)82:7<1352::aid-cncr19>3.0.co;2-5. Cancer. 1998. PMID: 9529028 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

343 results

Search Page

Filters